Integra LifeSciences

Regenerative medicine, surgical devices provider

Integra LifeSciences

Regenerative medicine, surgical devices provider

Overview

Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.

Funded Recently

Work here?Claim your company

About Integra LifeSciences

Simplify's Rating

Why Integra LifeSciences is rated

B-

Rated B on Competitive Edge

Rated B on Growth Potential

Rated C on Differentiation

Industries

BiotechnologyHealthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plainsboro Township, New Jersey

Founded

1989

Get referred to Integra LifeSciences

See people who can refer or advise you

Simplify's Take

What believers are saying

Q2 2026 revenue reached $391.9 million, with organic growth and raised EPS guidance.
S&P upgraded Integra to B on October 1, 2026, citing normalization progress.
Management targets $200 million operating cash flow in 2026, aided by cost savings.

What critics are saying

Cincinnati flooding cuts Q3 revenue $7 million and Q4 revenue $15 million to $20 million.
The Cincinnati plant returns only in Q2 2027, extending customer loss and backlog risk.
Boston cGMP securities litigation threatens damages, injunctions, and existential brand erosion.

What makes Integra LifeSciences unique

Integra spans neurosurgery, wound care, and reconstructive biologics, reducing single-product dependence.
Braintree's June 2026 ramp and Q4 2026 SurgiMend relaunch restore proprietary supply control.
2027 Liberties launch and SurgiMend PMA target create new neurosurgery and breast-reconstruction wedges.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1.4B

Above

Industry Average

Funded Over

3 Rounds

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!

Post IPO Debt Funding Comparison Coming Soon

Benefits

Medical Insurance
Dental Insurance
Vision Insurance
Short-Term Disability
Long-Term Disability
401(k) Retirement Plan

Stock Price

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth

Yahoo Finance

Oct 22nd, 2026

Integra LifeSciences shares fall 11% despite $411.2M Q3 revenue and return to profit

Integra LifeSciences shares fell about 11% in the first full session after its third-quarter 2026 results, as investors focused on refinancing worries and a high price-to-earnings ratio. Revenue rose to $411.2 million from $402.1 million a year earlier. The company posted a net profit of $14.9 million, against a $5.4 million loss, or basic earnings per share of $0.19. Operating cash flow reached $96 million, and net leverage fell to 3.8x. Net debt remains about $1.6 billion. Integra plans to refinance through new $450 million 9.5% notes, at an estimated 100 to 200 basis points higher rate. It also forecasts higher interest costs in 2027 and a softer fourth-quarter organic outlook.

Associated Press

Oct 9th, 2026

Integra prices $450M senior secured notes at 9.5% to refinance credit facilities

Integra LifeSciences Holdings Corporation has priced $450 million in senior secured notes due 2033, carrying a 9.500% interest rate. The medical technology company expects to close the sale on or around 19 October 2026, subject to customary closing conditions. The notes will be general senior secured obligations guaranteed by Integra's wholly-owned domestic subsidiaries that guarantee the company's existing senior secured credit facilities. Integra plans to use proceeds from the offering, combined with borrowings under new credit facilities, to refinance existing credit facilities and cover associated fees and expenses. The offering forms part of a broader refinancing transaction. The notes were offered only to qualified institutional buyers and certain non-US persons, relying on exemptions from Securities Act registration requirements. Integra LifeSciences is a global medical technology company specialising in neurosurgery and tissue reconstruction.

Associated Press

Oct 2nd, 2026

Integra LifeSciences cuts 2026 guidance after Cincinnati flooding disrupts production

Integra LifeSciences has lowered its full-year 2026 financial guidance following flooding at its Cincinnati manufacturing facility in July. The medical technology company now expects annual revenue of $1.634 billion to $1.654 billion, down from previous guidance of $1.654 billion to $1.695 billion. The flooding disrupted production of several products in the company's Specialty Surgical Technologies portfolio. Integra estimates the supply disruption reduced third quarter revenue by approximately $7 million and will impact fourth quarter revenue by $15 million to $20 million. The company expects third quarter revenue of $410 million to $412 million and adjusted earnings per share of $0.55 to $0.59. Full-year adjusted earnings per share guidance has been revised to $2.30 to $2.40, down from $2.40 to $2.50. Integra maintains property and business interruption insurance and expects recoveries to mitigate a substantial portion of the earnings impact. The facility is expected to return to full manufacturing operations during the second quarter of 2027.

MarketScreener

Oct 2nd, 2026

Integra LifeSciences Launches $600 Million Senior Secured Term Loan B

Integra LifeSciences said Friday that it has launched a $600 million seven-year senior secured term loan B as part of a broader refinancing transaction. The medical technology company said it...

Yahoo Finance

May 29th, 2026

Integra LifeSciences shares jump 6% after Citigroup upgrades rating and raises price target to $16

Integra LifeSciences shares rose 6.1% after Citigroup upgraded its rating from Sell to Neutral and raised its price target to $16 from $11. Analyst Joanne Wuensch's upgrade reflects reduced downside risk, though not yet a bullish outlook. The upgrade follows strong first-quarter 2026 results reported 22 days earlier, when the stock gained 5.3%. Integra's revenue grew 2.4% year-on-year to $391.9 million, beating estimates, whilst adjusted earnings per share of $0.54 exceeded consensus by 32.8%. The company raised its full-year earnings guidance and appointed Stuart Essig as CEO. Integra shares are up 36.7% year-to-date and recently hit a 52-week high of $16.42, though five-year returns remain significantly negative.

Recently Posted Jobs